logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produseast1
Showing 1 - 12 of 12 Items
Showing 1 - 12 of 12 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Acceptability of a new 4-in-1 Abacavir/Lamivudine/Lopinavir/Ritonavir paediatric fixed-dose combination: the caregiver–child dyads’ perspective

Rotsaert A, Ogara C, Mwanga-Amumpaire J, Kekitiinwa AR, Musiime V,  et al.
2023-01-01 • Therapeutic Advances in Infectious Disease
2023-01-01 • Therapeutic Advances in Infectious Disease
BACKGROUND
Worldwide, 1.7 million children younger than 15 years were living with HIV in 2021. Only 52% of them had access to antiretrovirals (ARVs). Lack of age-appropriate ARV form...
Journal Article
|
Commentary

Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries

Ford NP, Wiktor SZ, Kaplan K, Andrieux-Meyer I, Hill AM,  et al.
2015-05-18 • International Journal of Drug Policy
2015-05-18 • International Journal of Drug Policy
Journal Article
|
Commentary

Why it's time to say goodbye to Stavudine...everywhere

Andrieux-Meyer I, Clayden P, Collins S, Geffen N, Goemaere E,  et al.
2012-03-01 • Southern African Journal of HIV medicine
2012-03-01 • Southern African Journal of HIV medicine
Journal Article
|
Research

Extremely Low Hepatitis C prevalence among HIV co-infected individuals in 4 countries in sub-Saharan Africa

Loarec A, Carnimeo V, Molfino L, Kizito W, Muyindike WR,  et al.
2018-11-16 • AIDS
2018-11-16 • AIDS
: A multicentric, retrospective case-series analysis (facility-based) in five sites across Kenya, Malawi, Mozambique, and Uganda screened HIV-positive adults for hepatitis C virus (HCV) ...
Journal Article
|
Review

Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission

Cooke GS, Andrieux-Meyer I, Applegate TL, Atun R, Burry J,  et al.
2019-02-01 • Lancet Gastroenterology and Hepatology
2019-02-01 • Lancet Gastroenterology and Hepatology
Viral hepatitis is a major public health threat and a leading cause of death worldwide. Annual mortality from viral hepatitis is similar to that of other major infectious diseases such a...
Journal Article
|
Review

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Ford NP, Lee JS, Andrieux-Meyer I, Calmy A
2012-01-11 • HIV/AIDS - Research and Palliative Care
2012-01-11 • HIV/AIDS - Research and Palliative Care
Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to b...
Journal Article
|
Commentary

Preferred antiretroviral drugs for the next decade of scale up

Andrieux-Meyer I, Calmy A, Cahn P, Clayden P, Raguin G,  et al.
2012-09-18 • Journal of the International AIDS Society
2012-09-18 • Journal of the International AIDS Society
Global commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prev...
Journal Article
|
Commentary

Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries

Loyse A, Burry J, Cohn J, Ford NP, Chiller T,  et al.
2018-10-18 • Lancet Infectious Diseases
2018-10-18 • Lancet Infectious Diseases
In 2018, WHO issued guidelines for the diagnosis, prevention, and management of HIV-related cryptococcal disease. Two strategies are recommended to reduce the high mortality associated w...
Journal Article
|
Commentary

Getting HIV treatment to the most people

Lynch S, Ford NP, van Cutsem G, Bygrave H, Janssens B,  et al.
2012-07-20 • Science
2012-07-20 • Science
The new understanding that antiretroviral therapy (ART) can significantly reduce HIV transmission has stimulated scientific and political leaders to claim that ending the AIDS epidemic i...
Journal Article
|
Letter

Disparity in market prices for hepatitis C virus direct-acting drugs

Andrieux-Meyer I, Cohn J, de Araujo ES, Hamid SS
2015-11-01 • Lancet Global Health
2015-11-01 • Lancet Global Health
Journal Article
|
Review

Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings

Ford NP, Lee JS, Andrieux-Meyer I, Calmy A
2011-04-28 • HIV/AIDS - Research and Palliative Care
2011-04-28 • HIV/AIDS - Research and Palliative Care
The vast majority of people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome reside in the developing world, in settings characterized by limited health...
Journal Article
|
Review

Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis

Ford NP, Mofenson L, Shubber Z, Calmy A, Andrieux-Meyer I,  et al.
2011-11-28 • AIDS
2011-11-28 • AIDS
INTRODUCTION
Primate studies and some observational human data have raised concern regarding an association of first-trimester efavirenz exposure with central nervous system congenit...